EquityIndex FundsVery High Risk
Direct
NAV (27-May-25)
Returns (Since Inception)
Fund Size
₹160 Cr
Expense Ratio
0.51%
ISIN
INF754K01LV5
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
26 Oct 2020
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+10.82%
— (Cat Avg.)
3 Years
+17.65%
— (Cat Avg.)
Since Inception
+15.49%
— (Cat Avg.)
Equity | ₹158.8 Cr | 99.49% |
Others | ₹0.81 Cr | 0.51% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹20.85 Cr | 13.06% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹10.13 Cr | 6.34% |
Cipla Ltd | Equity | ₹9.65 Cr | 6.04% |
Eli Lilly and Co | Equity | ₹9.21 Cr | 5.77% |
Divi's Laboratories Ltd | Equity | ₹8.62 Cr | 5.40% |
Apollo Hospitals Enterprise Ltd | Equity | ₹8.33 Cr | 5.22% |
Dr Reddy's Laboratories Ltd | Equity | ₹8.2 Cr | 5.14% |
Lupin Ltd | Equity | ₹5.67 Cr | 3.55% |
Johnson & Johnson | Equity | ₹4.78 Cr | 2.99% |
Torrent Pharmaceuticals Ltd | Equity | ₹4.67 Cr | 2.92% |
AbbVie Inc | Equity | ₹4.38 Cr | 2.74% |
Fortis Healthcare Ltd | Equity | ₹3.99 Cr | 2.50% |
Aurobindo Pharma Ltd | Equity | ₹3.81 Cr | 2.39% |
Mankind Pharma Ltd | Equity | ₹3.62 Cr | 2.27% |
Abbott Laboratories | Equity | ₹2.85 Cr | 1.79% |
Novartis AG ADR | Equity | ₹2.84 Cr | 1.78% |
Merck & Co Inc | Equity | ₹2.74 Cr | 1.71% |
Novo Nordisk AS ADR | Equity | ₹2.72 Cr | 1.70% |
Zydus Lifesciences Ltd | Equity | ₹2.65 Cr | 1.66% |
Alkem Laboratories Ltd | Equity | ₹2.54 Cr | 1.59% |
Laurus Labs Ltd | Equity | ₹2.51 Cr | 1.57% |
Intuitive Surgical Inc | Equity | ₹2.33 Cr | 1.46% |
Ipca Laboratories Ltd | Equity | ₹2.32 Cr | 1.45% |
Glenmark Pharmaceuticals Ltd | Equity | ₹2.31 Cr | 1.45% |
Thermo Fisher Scientific Inc | Equity | ₹2.08 Cr | 1.31% |
Amgen Inc | Equity | ₹1.98 Cr | 1.24% |
Vertex Pharmaceuticals Inc | Equity | ₹1.66 Cr | 1.04% |
Gilead Sciences Inc | Equity | ₹1.66 Cr | 1.04% |
Danaher Corp | Equity | ₹1.64 Cr | 1.03% |
Stryker Corp | Equity | ₹1.63 Cr | 1.02% |
Biocon Ltd | Equity | ₹1.6 Cr | 1.00% |
Piramal Pharma Ltd | Equity | ₹1.49 Cr | 0.94% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.49 Cr | 0.93% |
Narayana Hrudayalaya Ltd | Equity | ₹1.48 Cr | 0.93% |
Ajanta Pharma Ltd | Equity | ₹1.4 Cr | 0.88% |
Medtronic PLC | Equity | ₹1.38 Cr | 0.86% |
Cohance Lifesciences Ltd | Equity | ₹1.37 Cr | 0.86% |
Syngene International Ltd | Equity | ₹1.36 Cr | 0.85% |
Gland Pharma Ltd | Equity | ₹1.23 Cr | 0.77% |
Global Health Ltd | Equity | ₹1.14 Cr | 0.72% |
Regeneron Pharmaceuticals Inc | Equity | ₹0.82 Cr | 0.51% |
Becton Dickinson & Co | Equity | ₹0.76 Cr | 0.48% |
Net Receivables/(Payables) | Cash - Repurchase Agreement | ₹0.48 Cr | 0.30% |
Agilent Technologies Inc | Equity | ₹0.39 Cr | 0.24% |
IQVIA Holdings Inc | Equity | ₹0.36 Cr | 0.22% |
Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹0.33 Cr | 0.21% |
Illumina Inc | Equity | ₹0.16 Cr | 0.10% |
Accrued Interest | Cash - Collateral | ₹0 Cr | 0.00% |
Large Cap Stocks
34.23%
Mid Cap Stocks
30.42%
Small Cap Stocks
5.79%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹158.8 Cr | 99.49% |
Standard Deviation
This fund
13.05%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
0.76
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since October 2021
Since February 2021
ISIN INF754K01LV5 | Expense Ratio 0.51% | Exit Load No Charges | Fund Size ₹160 Cr | Age 4 years 7 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark MSCI Ind Dom & Wld HealthC 45 NR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹1,65,204 Cr
Address
J.P.Morgan Tower, Mumbai, 400 098
Your principal amount will be at Very High Risk
EquityIndex FundsVery High Risk
Direct
NAV (27-May-25)
Returns (Since Inception)
Fund Size
₹160 Cr
Expense Ratio
0.51%
ISIN
INF754K01LV5
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
26 Oct 2020
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+10.82%
— (Cat Avg.)
3 Years
+17.65%
— (Cat Avg.)
Since Inception
+15.49%
— (Cat Avg.)
Equity | ₹158.8 Cr | 99.49% |
Others | ₹0.81 Cr | 0.51% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹20.85 Cr | 13.06% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹10.13 Cr | 6.34% |
Cipla Ltd | Equity | ₹9.65 Cr | 6.04% |
Eli Lilly and Co | Equity | ₹9.21 Cr | 5.77% |
Divi's Laboratories Ltd | Equity | ₹8.62 Cr | 5.40% |
Apollo Hospitals Enterprise Ltd | Equity | ₹8.33 Cr | 5.22% |
Dr Reddy's Laboratories Ltd | Equity | ₹8.2 Cr | 5.14% |
Lupin Ltd | Equity | ₹5.67 Cr | 3.55% |
Johnson & Johnson | Equity | ₹4.78 Cr | 2.99% |
Torrent Pharmaceuticals Ltd | Equity | ₹4.67 Cr | 2.92% |
AbbVie Inc | Equity | ₹4.38 Cr | 2.74% |
Fortis Healthcare Ltd | Equity | ₹3.99 Cr | 2.50% |
Aurobindo Pharma Ltd | Equity | ₹3.81 Cr | 2.39% |
Mankind Pharma Ltd | Equity | ₹3.62 Cr | 2.27% |
Abbott Laboratories | Equity | ₹2.85 Cr | 1.79% |
Novartis AG ADR | Equity | ₹2.84 Cr | 1.78% |
Merck & Co Inc | Equity | ₹2.74 Cr | 1.71% |
Novo Nordisk AS ADR | Equity | ₹2.72 Cr | 1.70% |
Zydus Lifesciences Ltd | Equity | ₹2.65 Cr | 1.66% |
Alkem Laboratories Ltd | Equity | ₹2.54 Cr | 1.59% |
Laurus Labs Ltd | Equity | ₹2.51 Cr | 1.57% |
Intuitive Surgical Inc | Equity | ₹2.33 Cr | 1.46% |
Ipca Laboratories Ltd | Equity | ₹2.32 Cr | 1.45% |
Glenmark Pharmaceuticals Ltd | Equity | ₹2.31 Cr | 1.45% |
Thermo Fisher Scientific Inc | Equity | ₹2.08 Cr | 1.31% |
Amgen Inc | Equity | ₹1.98 Cr | 1.24% |
Vertex Pharmaceuticals Inc | Equity | ₹1.66 Cr | 1.04% |
Gilead Sciences Inc | Equity | ₹1.66 Cr | 1.04% |
Danaher Corp | Equity | ₹1.64 Cr | 1.03% |
Stryker Corp | Equity | ₹1.63 Cr | 1.02% |
Biocon Ltd | Equity | ₹1.6 Cr | 1.00% |
Piramal Pharma Ltd | Equity | ₹1.49 Cr | 0.94% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.49 Cr | 0.93% |
Narayana Hrudayalaya Ltd | Equity | ₹1.48 Cr | 0.93% |
Ajanta Pharma Ltd | Equity | ₹1.4 Cr | 0.88% |
Medtronic PLC | Equity | ₹1.38 Cr | 0.86% |
Cohance Lifesciences Ltd | Equity | ₹1.37 Cr | 0.86% |
Syngene International Ltd | Equity | ₹1.36 Cr | 0.85% |
Gland Pharma Ltd | Equity | ₹1.23 Cr | 0.77% |
Global Health Ltd | Equity | ₹1.14 Cr | 0.72% |
Regeneron Pharmaceuticals Inc | Equity | ₹0.82 Cr | 0.51% |
Becton Dickinson & Co | Equity | ₹0.76 Cr | 0.48% |
Net Receivables/(Payables) | Cash - Repurchase Agreement | ₹0.48 Cr | 0.30% |
Agilent Technologies Inc | Equity | ₹0.39 Cr | 0.24% |
IQVIA Holdings Inc | Equity | ₹0.36 Cr | 0.22% |
Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹0.33 Cr | 0.21% |
Illumina Inc | Equity | ₹0.16 Cr | 0.10% |
Accrued Interest | Cash - Collateral | ₹0 Cr | 0.00% |
Large Cap Stocks
34.23%
Mid Cap Stocks
30.42%
Small Cap Stocks
5.79%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹158.8 Cr | 99.49% |
Standard Deviation
This fund
13.05%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
0.76
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since October 2021
Since February 2021
ISIN INF754K01LV5 | Expense Ratio 0.51% | Exit Load No Charges | Fund Size ₹160 Cr | Age 4 years 7 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark MSCI Ind Dom & Wld HealthC 45 NR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹1,65,204 Cr
Address
J.P.Morgan Tower, Mumbai, 400 098
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments